Side-by-side · Research reference
OvagenvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
ATheoreticalHUMAN-REVIEWED2/42 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
Ovagen
PT-141
Primary target
Ovarian tissue chromatin complexes
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
Presumed physiological — Khavinson peptides described as regulatory, not replacement
—
Origin
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
Ovagen
PT-141
Standard dose
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
PRN, max 8 doses / month
Evidence basis
Theoretical / Russian-tradition
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
PRN; reassess if no benefit after 8 doses
Route
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
—
Lower / starter dose
—
1 mg (off-label)
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
Ovagen
PT-141
Reported adverse events
None documented in indexed literature
—
Theoretical hormonal effects
Ovarian stimulation — monitor for estrogen-sensitive conditions
—
Injection site reaction
Possible mild erythema (SQ route)
Erythema, mild pain
Long-term safety
Unknown — no PubMed-indexed RCTs
—
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
Ovagen
PT-141
1. Oral route
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Subcutaneous route
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
SQ — abdomen or thigh.
3. Cyclical protocol
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
—
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.